Wegovy and IIH: the evidence, the risks, and what it means for you

Why weight loss matters so much in IIH, and what semaglutide data show

IIH occurs when cerebrospinal fluid pressure rises without an obvious cause such as a tumour or infection. Obesity is the single strongest modifiable risk factor: pressure inside the skull falls measurably when body weight falls, and the IIH Treatment Trial, published in The Lancet, established that a low-calorie diet producing around 25% weight loss reduced intracranial pressure by a clinically meaningful margin at three months. The biological mechanism involves adipose tissue influencing CSF secretion and venous sinus pressure, effects that are sensitive to even modest weight reduction.

Semaglutide, the active ingredient in Wegovy, was studied in the STEP 1 trial published in the New England Journal of Medicine, where adults with obesity achieved an average body-weight reduction of around 15% over 68 weeks, a scale of loss that, in IIH patients, would be expected to produce significant symptom relief. Smaller observational series and case reports have since described improvements in papilloedema and headache frequency in people with IIH who lost substantial weight on GLP-1 medicines, though these are not controlled trials. The NHS patient information for semaglutide sets out what is currently known about the medicine's effects and side-effect profile, and is worth reading alongside this page.

A dedicated clinical trial of semaglutide in IIH is actively recruiting in the UK; results are awaited. Until peer-reviewed data from that trial are published, prescribing decisions for people with IIH rely on extrapolation from the weight-loss evidence base and individual clinical judgement. That is not a reason to dismiss the option, it is a reason to make the decision carefully, with the right clinicians involved.

What makes Wegovy for IIH more complicated than weight loss alone

The interaction between semaglutide and IIH is not simply a matter of losing weight. Several practical considerations apply. First, many people with IIH take acetazolamide, topiramate or other medicines to lower intracranial pressure; as weight falls and symptoms improve, doses of those medicines often need adjusting, which requires neurology oversight. Second, headache is both a core symptom of IIH and a recognised common side effect of semaglutide, particularly in the first few weeks of treatment. Distinguishing a medication-related headache from a change in intracranial pressure needs clinical attention. Third, nausea and vomiting (the most frequently reported GI side effects of semaglutide-based treatment) can complicate hydration, and dehydration in turn may affect cerebrospinal fluid dynamics.

None of these considerations rules out Wegovy in IIH. They do mean the starting decision should involve the person's neurologist, not only a weight-management service. A prescribing clinician will want to know about current IIH medications, recent ophthalmology findings (fundoscopy or visual field tests), and whether intracranial pressure is currently controlled. People whose IIH is well-managed and whose main goal is sustained weight loss may be good candidates; people with rapidly progressive or poorly controlled IIH need specialist review first.

It is also worth reading about how long Wegovy is typically used, since sustained weight management is important in IIH, pressure tends to rise again if weight is regained after treatment stops.

Practical points if you have IIH and are exploring this option

The licensed weight-management criteria for Wegovy in the UK are a BMI of 30 or above, or 27 or above with at least one weight-related condition. IIH itself is a recognised weight-related condition, so it can contribute to meeting the eligibility threshold, though eligibility on paper is the starting point, not the finish line. A full clinical picture, including your current medications, your IIH management plan and your general health, shapes whether a prescriber considers it appropriate. You can read more about how Wegovy is structured as a treatment on the Wegovy overview page, including how the dose is built up from 0.25mg through to the 2.4mg maintenance level.

If you are already part-way through a titration schedule (for example, currently on the 1mg dose or the 2mg step) it matters that any monitoring of your IIH continues at the usual intervals; weight loss does not immediately normalise intracranial pressure, and symptom changes should be fed back to your neurology team. The NHS England guidance on weight-management injections covers general monitoring expectations and is the framework that clinicians working in this area follow.

On the practical side: Wegovy arrives in a pre-filled pen, dispatched in plain, unbranded packaging with DPD tracked delivery, and is stored in the fridge at home. The pen itself requires only a once-weekly injection at a consistent time, which most people find straightforward once they have been shown the technique. Storage and injection guidance is in the Patient Information Leaflet included with every pen.

Costs vary by dose; our Wegovy pricing page explains the current private market context honestly, including what a legitimate private prescription should include. If you are thinking about whether Wegovy might suit your situation, exploring the broader weight-loss treatment options first can be a helpful step before speaking to a prescriber.